About C4 Therapeutics
C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T’s internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.
Founder and CEO: Marc Cohen
Founders: Ken Anderson, Marc Cohen, Jay Bradner and Nathanael Gray
CSO: Andy Phillips
CAO: Andrea Armstrong
CBO: Tom Needham
Please click here for C4 job opportunities.
FOLLOW C4 THERAPEUTICS:
Tweets by C4 Therapeutics
36 articles with C4 Therapeutics
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced that it will present in a talk and roundtable discussion at the 3 rd Annual Targeted Protein Degradation Summit on October 14 and 15. Dr. Rhamy Zeid, C4T’s Director of Target Biology, will present during the translational portion of
C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
C4 Therapeutics , Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the closing of its initial public offering of 11.04 million shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1.44 million additional shares of common stock, at a public offering price o
Company stock began trading on the Nasdaq this morning under the ticker symbol CCCC. The upsized IPO is expected to close Oct. 6.
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the pricing of its upsized initial public offering of 9.6 million shares of common stock at a public offering price of $19 per share
9/11/2020Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
C4 Therapeutics, a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, announced the hiring of Andrew Hirsch as the Company’s incoming chief executive officer.
7/17/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M. Siegel to its leadership team as Chief Financial Officer and Chief Legal Officer, respectively. Mr. McKee currently also serves as Chief Executive Officer of MBJC Associates, LLC, a business
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform
C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the closing of a $170 million financing, including $150 million in Series B equity co-led by existing investor Cobro Ventures and new investor Perc
Bio-Techne Corporation announced the signing of an agreement with C4 Therapeutics, Inc. to acquire an exclusive license for the Achilles-TAG degradation platform.
C4 Therapeutics Announces the Addition of Ryan B. Corcoran, M.D., Ph.D. to the Scientific Advisory Board
Ryan Corcoran is a world leader in oncogenic signaling pathways
He brings three decades of experience leading global, multi-strategy organizations across a wide range of industries to C4T’s Board.
C4 Therapeutics (C4T) today announced the appointment of Adam Crystal M.D., Ph.D. as Chief Medical Officer. Dr. Crystal will oversee C4T’s activities relating to the clinical development of the company’s pipeline of targeted protein degraders.
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2017.
C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche
C4 Therapeutics announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
C4 Therapeutics (C4T) today announced that Stewart Fisher, Ph.D. has been promoted to Chief Scientific Officer